Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
52
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
With results exceeding management’s forecast for Q3, here’s what we think of Uber stock.
stocks
The largest share trading on the ASX remains materially overvalued
Profit barely budges on the most expensive bank in the world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.40 | 38.00 | -0.42% |
| CAC 40 | 8,156.23 | 0.00 | 0.00% |
| DAX 40 | 24,088.06 | 128.07 | 0.53% |
| Dow JONES (US) | 47,927.96 | 559.33 | 1.18% |
| FTSE 100 | 9,899.60 | 112.45 | 1.15% |
| HKSE | 26,870.00 | 173.59 | 0.65% |
| NASDAQ | 23,468.30 | 58.87 | -0.25% |
| Nikkei 225 | 50,970.16 | 127.23 | 0.25% |
| NZX 50 Index | 13,671.73 | 67.18 | 0.49% |
| S&P 500 | 6,846.61 | 14.18 | 0.21% |
| S&P/ASX 200 | 8,799.50 | 36.50 | -0.41% |
| SSE Composite Index | 3,997.14 | 5.62 | -0.14% |